Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

LONDON (Reuters) – The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more convenient option: A pill. Novo Nordisk already makes semaglutide ...

Novo Nordisk CEO Lars Fruergaard Jorgensen was speaking to journalists at the company's headquarters just outside Copenhagen after the company reported fourth-quarter earnings. Sign up here.

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.